51.25
-0.96 (-1.84%)
| Previous Close | 52.21 |
| Open | 52.66 |
| Volume | 1,253,658 |
| Avg. Volume (3M) | 2,603,182 |
| Market Cap | 6,315,076,096 |
| Price / Earnings (TTM) | 13.63 |
| Price / Earnings (Forward) | 11.00 |
| Price / Sales | 6.21 |
| Price / Book | 13.34 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Halozyme Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.18% |
| % Held by Institutions | 101.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Snyder Capital Management L P | 31 Mar 2025 | 3,674,302 |
| Alliancebernstein L.P. | 31 Mar 2025 | 3,215,109 |
| Macquarie Group Ltd | 31 Mar 2025 | 2,674,273 |
| Congress Asset Management Co | 31 Mar 2025 | 2,132,707 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 72.00 (HC Wainwright & Co., 40.49%) | Buy |
| Median | 62.00 (20.98%) | |
| Low | 47.00 (Leerink Partners, -8.29%) | Sell |
| Average | 60.80 (18.63%) | |
| Total | 1 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 56.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 May 2025 | 72.00 (40.49%) | Buy | 54.73 |
| 25 Apr 2025 | 72.00 (40.49%) | Buy | 60.49 | |
| Morgan Stanley | 14 May 2025 | 62.00 (20.98%) | Hold | 47.91 |
| Leerink Partners | 13 May 2025 | 47.00 (-8.29%) | Sell | 50.23 |
| Wells Fargo | 07 May 2025 | 65.00 (26.83%) | Hold | 70.14 |
| JP Morgan | 21 Apr 2025 | 58.00 (13.17%) | Hold | 57.29 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TORLEY HELEN | - | 53.17 | -60,000 | -3,190,200 |
| Aggregate Net Quantity | -60,000 | |||
| Aggregate Net Value ($) | -3,190,200 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 53.17 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 24 Jun 2025 | Automatic sell (-) | 20,000 | 53.90 | 1,078,000 |
| TORLEY HELEN | Officer | 24 Jun 2025 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 23 Jun 2025 | Automatic sell (-) | 20,000 | 52.80 | 1,056,000 |
| TORLEY HELEN | Officer | 23 Jun 2025 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 20 Jun 2025 | Automatic sell (-) | 20,000 | 52.81 | 1,056,200 |
| TORLEY HELEN | Officer | 20 Jun 2025 | Option execute | 20,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |